Free Trial
→ Out of 18,347 Cryptocurrencies... This is the ONLY One (From Crypto 101 Media) (Ad)tc pixel Free GMAB Stock Alerts

Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S logo
$27.82 -0.79 (-2.76%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$27.82 0.00 (0.00%)
As of 09/12/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Genmab A/S - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings
Sell
1
Hold
2
Buy
7

Based on 10 Wall Street analysts who have issued ratings for Genmab A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 2 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for GMAB.

Consensus Price Target

$39.25
41.09% Upside
According to the 10 analysts' twelve-month price targets for Genmab A/S, the average price target is $39.25. The highest price target for GMAB is $48.00, while the lowest price target for GMAB is $27.00. The average price target represents a forecasted upside of 41.09% from the current price of $27.82.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GMAB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMAB Analyst Ratings Over Time

TypeCurrent Forecast
9/13/24 to 9/13/25		1 Month Ago
8/14/24 to 8/14/25		3 Months Ago
6/15/24 to 6/15/25		1 Year Ago
9/14/23 to 9/13/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$39.25$37.80$39.17$45.20
Forecasted Upside41.09% Upside64.49% Upside71.63% Upside68.03% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyHold

GMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genmab A/S Stock vs. The Competition

TypeGenmab A/SMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside41.09% Upside17,489.59% Upside10.72% Upside
News Sentiment Rating
Positive News

See Recent GMAB News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/19/2025Zacks Research
0 of 5 stars		 DowngradeStrong-Buy ➝ Hold
8/15/2025HC Wainwright
1 of 5 stars
Raghuram Selvaraju
Not Rated
Boost TargetBuy$35.00 ➝ $36.00+56.66%
7/8/2025Truist Financial
3 of 5 stars
Asthika Goonewardene
Asthika Goonewardene
Not Rated
Boost TargetBuy$45.00 ➝ $46.00+115.71%
4/1/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
J. Smith
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform
3/11/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Matt Phipps
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
2/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
J. Chang
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Jonathan Chang
Jonathan Chang
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$27.00+37.13%
2/11/2025BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
V. Floc'h
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
11/8/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingOutperform$46.00 ➝ $48.00+110.25%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Q. Ding
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageBuy
9/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingEqual Weight$31.00 ➝ $31.00+15.63%
8/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingOverweight ➝ Neutral
7/15/2024Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
A. Campbell
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeSector Perform ➝ Outperform
6/27/2024BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$46.00 ➝ $47.00+83.09%
1/22/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeNeutral ➝ Sell
12/6/2023UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeNeutral ➝ Buy
11/10/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeHold ➝ Buy
11/8/2023DNB Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeSell ➝ Buy
10/12/2023Nordea Equity Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:31 PM ET.


Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com.

Genmab A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Genmab A/S:

  • The current stock price is around $25.85, reflecting a recent increase of 3.9%, which may indicate positive market sentiment.
  • Genmab A/S reported earnings per share of $0.54, surpassing analysts' expectations, which suggests strong financial performance and potential for growth.
  • The company has a solid market capitalization of approximately $16.58 billion, indicating a stable position in the market.
  • Recent investments from hedge funds, including a significant stake increase by Tema Etfs LLC, demonstrate growing institutional confidence in Genmab A/S.
  • Analysts have given Genmab A/S a "Moderate Buy" rating with a consensus price target of $37.60, suggesting potential upside for investors.

Genmab A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Genmab A/S for these reasons:

  • The company had revenue of $925 million, which fell short of analysts' expectations of $5.77 billion, indicating potential challenges in meeting market forecasts.
  • Genmab A/S has a relatively high price-to-earnings (P/E) ratio of 13.00, which may suggest that the stock is overvalued compared to its earnings.
  • Despite recent stock price increases, the stock has a beta of 0.93, indicating lower volatility but also potentially lower returns compared to the market.
  • With a price-to-earnings-growth (PEG) ratio of 7.22, the stock may be considered expensive relative to its growth rate, which could deter value-focused investors.
  • 7.07% of the stock is owned by hedge funds and institutional investors, which may lead to increased volatility if these investors decide to sell their stakes.

GMAB Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $39.25, with a high forecast of $48.00 and a low forecast of $27.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There is currently 1 sell rating, 2 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMAB shares.

According to analysts, Genmab A/S's stock has a predicted upside of 41.09% based on their 12-month stock forecasts.

Over the previous 90 days, Genmab A/S's stock had 1 downgrade by analysts.

Genmab A/S has been rated by research analysts at HC Wainwright, Truist Financial, and Zacks Research in the past 90 days.

Analysts like Genmab A/S less than other "medical" companies. The consensus rating score for Genmab A/S is 2.70 while the average consensus rating score for "medical" companies is 2.78. Learn more on how GMAB compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:GMAB) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel